Tim Waters, the COO of BioDerm, has asked his cost management team for a product-line profitability analysis

Question:

Tim Waters, the COO of BioDerm, has asked his cost management team for a product-line profitability analysis for his firm’s two products, Xderm and Yderm. The two skin care products require a large amount of research and development and advertising. After receiving the following statement from BioDerm’s auditor, Tim concludes that Xderm is the more profitable product and that perhaps cost-cutting measures should be applied to Yderm.




XdermYdermTotal





Sales$3,000,000$2,000,000$5,000,000
Cost of goods sold$1,900,000$1,600,000$3,500,000
 Gross profit$1,100,000$400,000$1,500,000
Research and development

$900,000
Selling expenses

$100,000
 Profit before taxes

$500,000










Percent of R&D & selling costs traceable to Xderm =80%


Required
1. Explain why Tim may be wrong in his assessment of the relative performances of the two products.
2. Suppose that 80 percent of the R&D and selling expenses are traceable to Xderm. Prepare life-cycle income statements for each product. What does this tell you about the importance of accurate life-cycle costing?
3. Consider again your answers in requirements 1 and 2 with the following additional information. R&D and selling expenses are substantially higher for Xderm because it is a new product. Tim has strongly supported development of the new product, including the high selling and R&D expenses. He has assured senior managers that the Xderm investment will pay off in improved profits for the firm. What are the ethical issues, if any, facing Tim as he reports to top management on the profitability of the firm’s twoproducts?

Fantastic news! We've Found the answer you've been seeking!

Step by Step Answer:

Related Book For  book-img-for-question

Cost management a strategic approach

ISBN: 978-0073526942

5th edition

Authors: Edward J. Blocher, David E. Stout, Gary Cokins

Question Posted: